Conditional survival analysis of patients with resected non-small cell lung cancer

被引:0
|
作者
Chaudhry, Talib [1 ]
Krishnan, Vaishnavi [1 ]
Donaldson, Andrew E. [1 ]
Palmisano, Zachary M. [1 ]
Basu, Sanjib [1 ]
Geissen, Nicole M. [1 ]
Karush, Justin M. [1 ]
Alex, Gillian C. [1 ]
Borgia, Jeffrey A. [2 ,3 ]
Liptay, Michael J. [1 ]
Seder, Christopher W. [1 ]
机构
[1] Rush Univ, Med Ctr, Dept Cardiovasc & Thorac Surg, Joan & Paul Rubschlager Bldg,6th Floor,1520 W Harr, Chicago, IL 60612 USA
[2] Rush Univ, Med Ctr, Dept Pathol, Chicago, IL USA
[3] Rush Univ, Med Ctr, Dept Anat & Cell Biol, Chicago, IL USA
来源
JTCVS OPEN | 2023年 / 16卷
关键词
non-small cell lung cancer; conditional sur- vival; conditional survival; prognosis; LONG-TERM SURVIVAL; RECURRENCE; PROBABILITY;
D O I
10.1016/j.xjon.2023.09.010
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Conditional survival (CS) analyses provide an estimate of survival accounting for years already survived after treatment. We aim to evaluate the difference between actuarial and conditional survival in patients following lung resection for non-small - small cell lung cancer (NSCLC). In addition, CS analyses are used to examine whether prognosticators of survival change over time following surgery. Methods: Patients who underwent anatomic lung resection at a single institution for pathologic stage I-IIIA NSCLC between 2010 and 2021 were identified; those who underwent wedge resection for node-negative tumors < 2 cm were also included. CS estimates were calculated as the probability of remaining disease- free after x years of nonrecurrence (CSx). Kaplan-Meier, log-rank, and Cox proportional hazard methods for examining CS were used for subgroup comparisons and assessing associations with baseline covariates. Results: Overall, 863 patients met the study inclusion criteria, with a median followup of 44.1 months. Conditional overall survival (OS) and disease-free survival (DFS) were greater than actuarial rates at all time points after surgery. At the time of resection, male sex (hazard ratio [HR], 1.33; 95% % confidence interval [CI], 1.03 to 1.72; P = .032), tumor size>3 cm (HR, 1.17; 95% % CI, 1.11-1.23; P < .001), node positivity (HR, 3.31; 95% % CI, 2.52-4.33; P < .001), and American Joint Committee on Cancer stage (P < .001) were associated with DFS. However, if a patient lived 3 years without recurrence (CS3), these factors were no longer prognostic of DFS. Conclusions: Conditional survival analyses provide dynamic assessments of OS and DFS after NSCLC resection. After 3 years without recurrence, certain characteristics associated with DFS at the time of surgery no longer prognosticate recurrence. (JTCVS Open 2023;16:948-59)
引用
收藏
页码:948 / 959
页数:12
相关论文
共 50 条
  • [41] Prognostic factors including lymphovascular invasion on survival for resected non-small cell lung cancer
    Okiror, Lawrence
    Harling, Leanne
    Toufektzian, Levon
    King, Juliet
    Routledge, Tom
    Harrison-Phipps, Karen
    Pilling, John
    Veres, Lukacs
    Lal, Ruchi
    Bille, Andrea
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2018, 156 (02): : 785 - 793
  • [42] Analysis of the prognostic role of an immune checkpoint score in resected non-small cell lung cancer patients
    Uso, Marta
    Jantus-Lewintre, Eloisa
    Calabuig-Farinas, Silvia
    Blasco, Ana
    Garcia del Olmo, Eva
    Guijarro, Ricardo
    Martorell, Miguel
    Camps, Carlos
    Sirera, Rafael
    ONCOIMMUNOLOGY, 2017, 6 (01):
  • [43] Improvement in Survival in Patients With Advanced Non-small Cell Lung Cancer
    Yoshida, Keishi
    Watanabe, Kaoru
    Nishimura, Taku
    Ikushima, Hiroaki
    Ohara, Sayaka
    Takeshima, Hideyuki
    Sakatani, Toshio
    Usui, Kazuhiro
    ANTICANCER RESEARCH, 2025, 45 (01) : 295 - 305
  • [44] Survival in patients with non-small cell lung cancer and brain metastases
    Lwin, M. Thit
    Bradley, K.
    Wright, S.
    Laurence, V.
    LUNG CANCER, 2010, 67 : S32 - S32
  • [45] Survival of Patients with Non-small Cell Lung Cancer and Brain Metastases
    Mulvenna, P.
    Barton, R.
    Wilson, P.
    Faivre-Finn, C.
    Nankivell, M.
    Stephens, R.
    Langley, R.
    Moore, B.
    Ardron, D.
    CLINICAL ONCOLOGY, 2011, 23 (05) : 375 - 376
  • [46] The effect of radiotherapy on the survival of non-small cell lung cancer patients
    Schaafsma, J
    Coy, P
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1998, 41 (02): : 291 - 298
  • [47] Local treatment of oligometastatic recurrence in patients with resected non-small cell lung cancer
    Yano, Tokujiro
    Okamoto, Tatsuro
    Haro, Akira
    Fukuyama, Seiichi
    Yoshida, Tsukihisa
    Kohno, Mikihiro
    Maehara, Yoshihiko
    LUNG CANCER, 2013, 82 (03) : 431 - 435
  • [48] Thoracic irradiation for patients with resected non-small cell lung cancer: Adjuvant or salvage?
    Wagner, Henry, Jr.
    CANCER JOURNAL, 2006, 12 (04): : 253 - 256
  • [49] Use and Impact of Adjuvant Chemotherapy in Patients With Resected Non-Small Cell Lung Cancer
    Williams, Christina D.
    Gajra, Ajeet
    Ganti, Apar K.
    Kelley, Michael J.
    CANCER, 2014, 120 (13) : 1939 - 1947
  • [50] Adjuvant cellular immunotherapy in patients with resected primary non-small cell lung cancer
    Pan, Qiu-Zhong
    Tang, Yan
    Wang, Qi-Jing
    Li, Yong-Qiang
    Zhang, Li
    Li, Xiao-Dong
    Zhao, Jing-Jing
    Weng, De-Sheng
    Liu, Qing
    Huang, Li-Xi
    He, Jia
    Chen, Shi-Ping
    Ke, Miao-La
    Zeng, Yi-Xin
    Xia, Jian-Chuan
    ONCOIMMUNOLOGY, 2015, 4 (09): : 1 - 8